http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20100028643-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6869 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2008-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17ec5eee90557f4d4b1c1cfe34e8ca83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fec23b4c5f7e71b7c2e24e8ce2d3081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c295708d366be0d91cd5ea608e07342 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80659d7ad248d0f50c0cd2331ced1b14 |
| publicationDate | 2010-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20100028643-A |
| titleOfInvention | Anti-cancer cytotoxic monoclonal antibodies |
| abstract | Antibody mediated lethality of cancer cells is an effective approach for treating cancer. Antibodies generated in mice upon immunization with ovarian cancer cells are screened for cytotoxicity against various cancer cell lines as endpoints. Anti-cancer cytotoxic monoclonal antibodies, produced by hybridoma AR104A1289.2.2 deposited with IDAC 190607-04, are isolated, which are cytotoxic to colon cancer cell lines and are animal models of human pancreatic, breast and prostate cancer Reduces tumor abundance in The monoclonal antibodies also bind to several cancer cell lines. The monoclonal antibodies bind to non-cancer cell lines but do not cause cytotoxicity to non-cancer cell lines. The monoclonal antibodies can be used to aid in the staged and diagnosed cancer and can be used to treat primary tumors and tumor metastases. The cytotoxic monoclonal antibodies can also be used to deliver toxins, enzymes, radioactive compounds and hematopoietic cells to cancer cells and further assist in reducing tumor burden. |
| priorityDate | 2007-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 341.